Same old Proulx, good talker but he has squandered this opportunity that was handed to him.
The problem I have with this change of its core business is not the idea of having a non-invasive way of diagnosing cancer in the lymph nodes, this is a wonderful achievement, if it is proven out with more than just a few patients in a seemingly difficult study now going on for three years?
Proulx fails to mention the risks, which are many, starting with the competiton with more $$$ who can quickly capitalize on this achievement with more resources and very skilled management. He does add this in the IBX website, but I see this as more cover his bu-- after all how many investors actually look at the site on a daily basis, when you have the magical oz behind the curtain, pumping out videos.
What are the main risks associated with this shift?
We will face the same risks associated with new product entry in established and entrenched markets where low-cost ultrasound is ubiquitous despite performance limitations. However, we believe introduction for use with MRI will reduce those risks compared to introducing a new technology. We are not aware of other players trying to address the unmet medical need that we are by molecular imaging and hence expect to benefit from being the first mover and potentially obtain regulatory exclusivity in certain jurisdictions if approved first.
Same risks as new products
Not aware of competitors, which means there is nothing proprietary that IBX has that others can't quickly copy.
So how many years now and millions and millions spent on a technology that he couldn't make work and now he realizes that the non-proprietary nanoparticles work with MRI. I hope I am dead wrong and the SP flies to the moon, but without a partner like Siemens or some big name, this will be another nano particle company, not what I invested $$ into.
News 
Market Data 
Discover 
